Short Interest Worth Watching: Akari Therapeutics Plc Adr (NASDAQ:AKTX) Shorted Shares Increased 2.87% After Market Selling

November 23, 2016 - By Louis Casey   ·   0 Comments

Short Interest Worth Watching: Akari Therapeutics Plc Adr (NASDAQ:AKTX) Shorted Shares Increased 2.87% After Market Selling

The stock of Akari Therapeutics Plc Adr (NASDAQ:AKTX) registered an increase of 2.87% in short interest. AKTX’s total short interest was 25,100 shares in November as published by FINRA. Its up 2.87% from 24,400 shares, reported previously. With 2,100 shares average volume, it will take short sellers 12 days to cover their AKTX’s short positions. The short interest to Akari Therapeutics Plc Adr’s float is 0.74%. The stock decreased 4.65% or $0.39 on November 23, hitting $7.99. About 415 shares traded hands. Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) has declined 52.66% since April 21, 2016 and is downtrending. It has underperformed by 57.98% the S&P500.

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. The company has a market cap of $101.35 million. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 , including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome. It currently has negative earnings. The Company’s lead drug, Coversin, a complement inhibitor, acts on complement C5, preventing release of C5a and formation of C5b-9.

AKTX Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, incorporated on October 7, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria (PNH), Guillain Barre syndrome (GBS) and atypical Hemolytic Uremic Syndrome (aHUS).

More notable recent Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) news were published by: Investorplace.com which released: “13 Pharmaceuticals Stocks to Sell Now” on September 23, 2016, also Investorplace.com with their article: “16 Pharmaceuticals Stocks to Sell Now” published on August 26, 2016, Reuters.com published: “Akari Therapeutics announces receipt of orphan drug designation for Coversin from U.S. FDA” on September 12, 2016. More interesting news about Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) were released by: Reuters.com and their article: “Akari Therapeutics treatment of guillain barré gets orphan drug status” published on May 12, 2016 as well as Reuters.com‘s news article titled: “Celsus Therapeutics completes acquisition of Volution Immuno Pharmaceuticals SA – Form 8-K” with publication date: September 21, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>